News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunomedics, Inc. (IMMU) Presents Epratuzumab's Mechanism of Action in Systemic Lupus Erythematosus


6/13/2013 8:46:27 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MADRID, Spain, June 13, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, mediates the reduction of select proteins on the surface of B cells via a process known as trogocytosis, and that such reduction could modulate B-cell activities.Results from this study were presented by Edmund A. Rossi, Ph.D., Executive Director, Recombinant Technology.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES